Edgewise Therapeutics, Inc. (EWTX) Dividend History

Company News

• Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

  Edgewise Therapeutics' (EWTX) share price surged 50% in a single session due to positive results from early trials of its novel treatment for obstructive hypertrophic cardiomyopathy, a leading cause of sudden cardiac-related death in young people. The company's pipeline and strong financial position also contribute to the positive sentiment.

  Benzinga
• Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

  Bausch & Lomb and Edgewise Therapeutics were among the top 7 mid-cap stock gainers last week, with Edgewise Therapeutics shares rocketing 50.19% after announcing positive topline data from a clinical trial, and Bausch & Lomb's parent company Bausch Health considering a sale.

  Benzinga

  Featured Companies: BHC BLCO
• Why Edgewise Therapeutics Stock Is Up 50% on Thursday

  Edgewise Therapeutics' cardiac drug EDG-7500 shows promise in clinical trials for treating obstructive hypertrophic cardiomyopathy, a condition marked by thickening of the left heart ventricle wall. The drug was well-tolerated and did not lead to lowered left ventricular ejection fraction levels, a common issue with other cardiac drugs. However, any potential commercialization is still years away.

  The Motley Fool
• Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

  The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  Zacks Investment Research
• Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?

  The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research